[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JOP20180117B1 - أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها - Google Patents

أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها

Info

Publication number
JOP20180117B1
JOP20180117B1 JOP/2018/0117A JOP20180117A JOP20180117B1 JO P20180117 B1 JOP20180117 B1 JO P20180117B1 JO P20180117 A JOP20180117 A JO P20180117A JO P20180117 B1 JOP20180117 B1 JO P20180117B1
Authority
JO
Jordan
Prior art keywords
methods
antibodies specific
hyperphosphorylated tau
tau
hyperphosphorylated
Prior art date
Application number
JOP/2018/0117A
Other languages
English (en)
Inventor
Jan Torleif Pedersen
Kristian Kjaergaard
Lars Ostergaard Pedersen
Nina Helen Rosenqvist
Justus Claus Alfred Daechsel
Karsten Juhl
Lena Tagmose
Mauro Marigo
Thomas Jensen
Soren Christensen
Laurent David
Christiane Volbracht
Lone Helbo
Abdur-Rasheed Asuni Ayodeji
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of JOP20180117A1 publication Critical patent/JOP20180117A1/ar
Application granted granted Critical
Publication of JOP20180117B1 publication Critical patent/JOP20180117B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

يتعلق الاختراع الحالي بفئة من جسم مضاد أحادي النسيلة يرتبط بالوحدة البنائية سيرين 396 المعالجة بفوسفوريلات على tau مرضي فائق المعالجة بفوسفوريلات (PHF) (pS396) مع ألفة محسنة، بالإضافة إلى طرق استخدام هذه الجزيئات وشظايا ربط tau منها في علاج مرض ألزهايمر وأمراض tau أخرى.
JOP/2018/0117A 2016-07-12 2017-07-07 أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها JOP20180117B1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201600416 2016-07-12
DKPA201700008 2017-01-04
DKPA201700005 2017-01-04
DKPA201700179 2017-03-14
PCT/EP2017/067067 WO2018011073A1 (en) 2016-07-12 2017-07-07 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Publications (2)

Publication Number Publication Date
JOP20180117A1 JOP20180117A1 (ar) 2019-01-30
JOP20180117B1 true JOP20180117B1 (ar) 2022-03-14

Family

ID=60941665

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0117A JOP20180117B1 (ar) 2016-07-12 2017-07-07 أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها

Country Status (40)

Country Link
US (5) US10472415B2 (ar)
EP (2) EP3484916B1 (ar)
JP (2) JP7029415B2 (ar)
KR (1) KR102551971B1 (ar)
CN (2) CN116041504A (ar)
AU (2) AU2017295608B2 (ar)
BR (1) BR112018004916A2 (ar)
CA (1) CA3027561A1 (ar)
CL (1) CL2019000082A1 (ar)
CO (1) CO2018014325A2 (ar)
CY (1) CY1123995T1 (ar)
DK (1) DK3484916T3 (ar)
DO (1) DOP2018000281A (ar)
EC (1) ECSP19005417A (ar)
ES (1) ES2862427T3 (ar)
GE (1) GEP20217222B (ar)
HR (1) HRP20210522T1 (ar)
HU (1) HUE053679T2 (ar)
IL (1) IL263530B2 (ar)
JO (1) JOP20180117B1 (ar)
LT (1) LT3484916T (ar)
MA (2) MA56165A (ar)
MX (1) MX2019000476A (ar)
MY (1) MY197836A (ar)
NI (1) NI201900003A (ar)
NZ (1) NZ748983A (ar)
PE (1) PE20190227A1 (ar)
PH (1) PH12018502613A1 (ar)
PL (1) PL3484916T3 (ar)
PT (1) PT3484916T (ar)
RS (1) RS61646B1 (ar)
RU (1) RU2760875C1 (ar)
SG (1) SG11201811015RA (ar)
SI (1) SI3484916T1 (ar)
SV (1) SV2019005807A (ar)
TN (1) TN2018000419A1 (ar)
TW (1) TWI747922B (ar)
UA (1) UA124104C2 (ar)
WO (1) WO2018011073A1 (ar)
ZA (1) ZA201808329B (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012397435B2 (en) 2012-12-21 2017-03-30 National Institutes For Quantum And Radiological Science And Technology Novel compound for imaging TAU protein accumulated in the brain
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CA3027561A1 (en) 2016-07-12 2018-01-18 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
KR102645073B1 (ko) 2016-12-07 2024-03-11 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
TW202328181A (zh) 2016-12-07 2023-07-16 美商建南德克公司 抗-tau抗體及使用方法
MA47205A (fr) 2017-01-04 2019-11-13 H Lundbeck As Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
MA50397A (fr) 2017-10-16 2020-08-26 Eisai R&D Man Co Ltd Anticorps anti-tau et leurs utilisations
AU2019214370A1 (en) * 2018-02-01 2020-07-30 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
BR112020018112A2 (pt) * 2018-03-05 2020-12-22 Janssen Pharmaceutica Nv Anticorpos anti-phf-tau e usos dos mesmos
AU2019265346B2 (en) 2018-05-09 2022-06-16 Aprinoia Therapeutics Limited Heteroaryl compounds and uses thereof
US20220041697A1 (en) * 2018-12-10 2022-02-10 New York University Monoclonal antibodies targeting c-terminal region of phosphorylated tau
CN113748343A (zh) 2019-03-28 2021-12-03 H.隆德贝克有限公司 pS396测定用于诊断TAU蛋白病的用途
TWI780464B (zh) * 2019-08-06 2022-10-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
AU2020383593A1 (en) 2019-11-13 2022-06-09 Aprinoia Therapeutics Limited Compounds for degrading Tau protein aggregates and uses thereof
CA3227440A1 (en) 2021-07-27 2023-02-02 Stand Therapeutics Co., Ltd. Peptide tag and nucleic acid encoding same

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
JPH07507044A (ja) 1991-12-06 1995-08-03 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ヴィッセンシャフテン エー.ヴェー. アルツハイマー病の診断および治療用の新規な手段
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
AU2753100A (en) 1999-02-03 2000-08-25 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
ATE384744T1 (de) 1999-07-29 2008-02-15 Medarex Inc Menschliche antikörper gegen her2/neu
DK1212422T3 (da) 1999-08-24 2007-07-02 Medarex Inc Humane CTLA-4-antistoffer og anvendelserne deraf
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP2009506302A (ja) 2005-08-04 2009-02-12 イェシバ・ユニバーシティ Ablによるタウのリン酸化
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
EP2185592B1 (en) * 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
SI2625198T1 (sl) * 2010-10-07 2015-11-30 Ac Immune S.A. Epfl Innovation Park Protitelesa, ki prepoznavajo fosfo-tau
EA031698B1 (ru) 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
JP6457263B2 (ja) * 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
CA2850686C (en) * 2011-10-07 2020-09-08 Ac Immune S.A. Phosphospecific antibodies recognising tau
BR112014024769A2 (pt) 2012-04-05 2017-12-12 Ac Immune Sa anticorpo humanizado tau
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
KR102313513B1 (ko) 2013-03-13 2021-10-15 프로테나 바이오사이언시즈 리미티드 Tau 면역치료제
WO2014170549A1 (en) 2013-04-16 2014-10-23 Glykos Finland Oy A method for generating induced pluripotent stem cells
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
EP3098242B1 (en) 2014-01-23 2018-08-29 Asahi Kasei Kabushiki Kaisha Block copolymer composition and adhesive composition
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CA3027561A1 (en) 2016-07-12 2018-01-18 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
MA47205A (fr) 2017-01-04 2019-11-13 H Lundbeck As Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Also Published As

Publication number Publication date
AU2017295608A1 (en) 2018-12-20
NI201900003A (es) 2020-04-27
US11111290B2 (en) 2021-09-07
US20190284266A1 (en) 2019-09-19
MA45655A (fr) 2019-05-22
EP3484916B1 (en) 2021-03-03
US10472415B2 (en) 2019-11-12
AU2024201450A1 (en) 2024-03-28
DOP2018000281A (es) 2019-02-15
US20180016330A1 (en) 2018-01-18
WO2018011073A1 (en) 2018-01-18
UA124104C2 (uk) 2021-07-21
NZ748983A (en) 2022-12-23
EP3484916A1 (en) 2019-05-22
HRP20210522T1 (hr) 2021-05-14
PL3484916T3 (pl) 2021-07-19
CA3027561A1 (en) 2018-01-18
IL263530B (en) 2022-10-01
PE20190227A1 (es) 2019-02-13
LT3484916T (lt) 2021-04-26
RU2760875C1 (ru) 2021-12-01
JP7244600B2 (ja) 2023-03-22
MX2019000476A (es) 2019-06-10
US20190284265A1 (en) 2019-09-19
MY197836A (en) 2023-07-20
PH12018502613A1 (en) 2019-09-30
KR102551971B1 (ko) 2023-07-07
MA45655B1 (fr) 2021-04-30
RS61646B1 (sr) 2021-04-29
PT3484916T (pt) 2021-03-31
IL263530B2 (en) 2023-02-01
SI3484916T1 (sl) 2021-08-31
IL263530A (en) 2019-01-31
US10647762B2 (en) 2020-05-12
CY1123995T1 (el) 2022-05-27
CN109618556B (zh) 2022-10-21
CN109618556A (zh) 2019-04-12
AU2017295608B2 (en) 2024-01-04
US12129289B2 (en) 2024-10-29
DK3484916T3 (da) 2021-04-06
GEP20217222B (en) 2021-02-10
CO2018014325A2 (es) 2019-01-18
ZA201808329B (en) 2020-02-26
SG11201811015RA (en) 2019-01-30
JP2019529336A (ja) 2019-10-17
KR20190028436A (ko) 2019-03-18
EP3878864A1 (en) 2021-09-15
JP7029415B2 (ja) 2022-03-03
MA56165A (fr) 2022-04-20
TN2018000419A1 (en) 2020-06-15
TW201809004A (zh) 2018-03-16
BR112018004916A2 (pt) 2018-12-11
ES2862427T3 (es) 2021-10-07
US20200109192A1 (en) 2020-04-09
CN116041504A (zh) 2023-05-02
TWI747922B (zh) 2021-12-01
ECSP19005417A (es) 2019-01-31
JOP20180117A1 (ar) 2019-01-30
HUE053679T2 (hu) 2021-07-28
CL2019000082A1 (es) 2019-04-05
US20220177557A1 (en) 2022-06-09
JP2022023096A (ja) 2022-02-07
SV2019005807A (es) 2019-02-13
US10487142B2 (en) 2019-11-26

Similar Documents

Publication Publication Date Title
PH12018502613A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
PH12018500062A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
MX2019005911A (es) Anticuerpos anti_cd137 novedosos y usos de estos.
MY194997A (en) Anti-ccr7 antibody drug conjugates
PE20170768A1 (es) Anticuerpos de union a protofibrillas ab mejorados
EA202191666A1 (ru) Антитела к il-27 и их применение
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2018014560A (es) Metodos para el tratamiento de la miastenia gravis generalizada refractaria.
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
CR20190012A (es) Anticuerpos específicos para la tauy hiperfosforilada y sus métodos de uso
AR109258A1 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
EA201892570A1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
EA201991020A2 (ru) Применение семафорин-4d-связывающих молекул для лечения нейродегенеративных нарушений